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The number of proteins found in body fluids and at cell surfaces, which are known to display carbohydrate-binding prop- 
erties, continues to increase rapidly. In these proteins, in addition to a domain associated with lectin properties, one or 
more, non-lectin domains are present. It is possible that binding of sugar residues by the lectin domain may be important 
in triggering a variety of recognition and clearance mechanisms via the non-lectin domains. The group of lectins contain- 
ing collagen-like sequences may provide some insight into structure/function relationships of the different domains in 
view of the well defined structures already available for several of these molecules. 
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1. INTRODUCTION 
Lectins, defined as carbohydrate-binding pro- 
teins of non-immune origin that agglutinate cells 
and/or precipitate polysaccharides and glycopro- 
teins [ 11, were first described in 1888 when a plant 
lectin (a phytohaemagglutinin) isolated from 
castor oil seeds, was shown to agglutinate 
erythrocytes. At the turn of the century the first 
vertebrate lectin, conglutinin, was described and 
characterized as the component of ox serum which 
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promoted agglutination of erythrocytes coated 
with activated complement components 121. 
However, the difficulty of demonstrating the 
presence of conglutinin activity in other species 
resulted in this mammalian lectin attracting only 
limited attention. The discovery of a membrane 
bound lectin, the galactosyl receptor, in 1974 [3] 
initiated intensive research for other vertebrate lec- 
tins, which has resulted in the discovery of quite a 
wide variety of both membrane bound and soluble 
lectins (see table 1). The current interest in lectins 
has been stimulated by the belief that they may be 
involved in recognition in a variety of biological 
systems (reflecting the numerous oligomeric car- 
bohydrates present on soluble as well as membrane 
associated proteins) and that the recognition event 
may in certain cases trigger effector functions. 
2. MAMMALIAN LECTINS 
Examples of the mammalian lectins which have 
been well characterized, are given in table 1. On 
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Table 1 
Carbohydrate binding proteins with and without collagen-like domains 
Soluble Membrane bound 
Found in plasma or Sugar specificity Lectin-typea . Membrane bound Sugar specificity Lectin-type 
other body fluids ‘C’, ‘S’ or ‘C’, 5’ or 
neither (‘N’) neither (‘N’) 
Collagen-like mannan binding mannan binding 
domain protein mannose/NADG C protein (hepatic 
present lung surfactant membrane asso- 
protein mannose/fucose C ciated form) mannose/NADG C 
conglutinin NADG/mannose C 
m21b galactans N 
Do not show serum amyloid P galactosyl receptor galactose/NAD gal C 
the presence component (SAP) MOflDG’ and mannose-6-P-re- 
of collagen- mannose ter- N ceptors (found in a 
like strut- cartilage proteoglycan minated structures large Ca’+depen- 
ture core protein C dent, and a small 
fibroblast proteo- fucose/galactose Car+ indepen- 
glycan core protein C dent form) mannosed-phosphate N 
,8-galactosidase MEL-14 antigen mannose-6-phosphate C 
specific lectin mannose specific 
(Ca’+ independent) ,8-D-galactosyl p- lectind (macro- 
thiogalactopyrano- S phage derived) 
side/lactose (in fucose binding lectin mannose not known 
presence of re- ligatind fucose C 
ducing agents) o-glucose-l-phos- 
complement receptor phate not known 
type 3 P-glucan N 
a Lectin type of ‘C’ or ‘S’ is based on the presence of certain conserved residues in the lectin domain as defined by Drickamer [4] 
b Although there are reports that Clq has lectin activity this point is not absolutely clear especially since recent work [34] indicates 
that a peptide sequence in the Fc region of IgG, which is free of carbohydrate serves as an inhibitor of Clq binding 
’ MO@DG: methyl 4,6-O-(l-carboxyethylidene)-P_D-galactopyranoside 
d Full structures have not yet been established for these molecules, therefore the possibility of the presence of collagen-like structure 
cannot be completely excluded 
the basis of structural and functional studies they 
can be considered to fall into three general 
categories as defined by Drickamer [4]: the ‘C- 
type’, which show Ca2+ dependence and contain a 
130 amino-acid-long domain which has a 
framework sequence of 18 conserved amino acid 
residues (fig.l), as seen in proteins such as the 
galactosyl receptor; the ‘S-type’, which do not 
show Ca2+ dependence but are thiol dependent and 
contain an approx. 100 amino-acid-long domain 
which has a framework sequence of 39 conserved 
amino acid residues (distinct from the ‘C-type’), as 
seen in proteins such as the different ,&galactoside 
specific lectins; a third group which does not show 
the presence of either C-type or S-type conserved 
residues and includes proteins such as serum 
amyloid protein and the mannosed-phosphate 
receptor (which is identical to the IGF-II receptor). 
The precise functions of most of these lectins 
after binding the appropriate carbohydrate ligands 
are not known, but the following roles have been 
proposed for several of the membrane bound lec- 
tins: elimination of aged desialylated erythrocytes 
and glycoconjugates showing exposed galactose 
groups, by the galactosyl receptor (also named 
asialoglycoprotein receptor) [5]; endocytosis of 
mannose/N-acetylglucosamine t rminated glyco- 
conjugates by the mannose specific lectin found on 
macrophages [6]; phagocytosis of yeast particles 
by complement receptor type 3 171; intracellular 
localization of lysosomal enzymes containing 
mannose-6-phosphate groups by mannose-6-phos- 
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r---- _____--ss------_-____ 20 aa 30 aa 15aa 6aa 5 aa 2 aa 
NH, -G-------~-----------GXXD------T----WXXXXP--~~GXXECXXXXXXG---WNDXX~XXXXXXXCE-COOH 
L___________________-----_--_________________------l 
Fig.1. The conserved residues in COOH-terminal carbohydrate-recognizing domains (C-type). Positions denoted as X are variable 
residues within sections of constant length containing highly conserved residues. The number of amino acids found between these 
sections containing conserved residues is variable and in each case is indicated by - - - plus the average number of amino acids found 
as calculated from the sequences of the proteins detailed below. The conserved residues are found in the galactosyl receptor, chicken 
hepatic lectin, membrane associated and serum MBP, fucose specific lectin (Mr 88-form), SP-A, flesh fly lectin, sea urchin lectin, 
cartilage proteoglycan core protein, fibroblast proteoglycan core protein, lymphocyte IgE FcR receptor, pancreatic stone protein and 
thrombomodulin, ELAM-1, GMP-140 and MEL-14 antigen [4,11-13,37,38]. 
phate receptors [8]. Some of the soluble lectins are 
also probably involved in clearance mechanisms as 
described below for those lectins containing 
collagen-like sequences and as seen with serum 
amyloid P component and C reactive protein 
which bind to a variety of polysaccharides 
represented on diverse bacteria, fungi and 
parasites [9]. ,&Galactoside specific lectins are of 
interest in that, besides other properties, they have 
been shown to be mitogenic to plasma cells [lo]. A 
new family of adhesion proteins has recently been 
described (ELAM-1, GMP-140 and the MEL-14 
antigen) which are each characterized by contain- 
ing a single C-type lectin domain, near the N- 
terminal end of the molecule, linked to an EGF do- 
main and between 2 and 9 domains of the type 
found in the complement proteins which bind C3b 
and/or C4b [ 1 l- 131. These newly described adhe- 
sion proteins appear to be involved in directing 
leukocytes to their appropriate sites in the body. 
It is possible that a clear understanding of some 
of the roles which lectins play after binding car- 
bohydrate will soon be achieved from studies car- 
ried out on those lectins containing collagen-like 
regions since this distinctive structural feature 
allows the construction of accurate molecular 
models. 
3. LECTINS CONTAINING COLLAGEN-LIKE 
SEQUENCES 
Both the membrane associated, hepatocyte 
form, of mannan binding protein and the serum 
form have been found to contain collagen-like se- 
quences and a C-type lectin domain, within the 
same polypeptide chain (table 1, fig.2). These 
calcium-dependent, mannose and iV-acetyl-D- 
glucosamine specific lectins are designated 
mannan-binding proteins (MBPs) because of their 
80 
specificity for yeast mannan. They exist as 
polymeric molecules having polypeptide chains of 
approx. 30 kDa. In these MBPs each chain is com- 
posed of a NH?-terminal end followed by a 
collagen-like domain and finally a COOH-terminal 
globular domain 1141 (cf. the serum form of MBP 
in fig.2). 
It has been shown that the mannose-binding 
portion of the membrane associated MBP is 
located in the COOH-terminal non-collagen-like 
domain which contains the lectin C-type conserved 
residues [14]. 
The serum form of MBP has been characterised 
in man, cows and rabbits and is similar to the 
hepatic form with respect to binding specificity, 
pH and calcium ion dependence. They show im- 
munochemical cross-reactivity and they are com- 
parable in the size of their subunits, but differ 
from each other in the number of subunits per pro- 
tein (the serum MBP being the larger of the two 
molecules). Human and rat soluble MBPs show 
approx. 60% identity over the first 20 residues of 
the NH2 terminal sequences made by direct 
analysis at the protein level and by cDNA cloning 
studies [15] they show approx. 50% overall identi- 
ty. The serum MBP is unusual for a plasma protein 
in that it has regions of collagen-like amino acid se- 
quence (i.e. regions of repetitive -Gly-Xaa-Yaa- se- 
quences). Two other plasma proteins, conglutinin 
[ 161 and complement component Clq [17], and 
also pulmonary surfactant apoprotein SP-A [ 181, 
have been shown to contain collagen-like features 
(fig.2). As indicated in table 1 these proteins can be 
classified as lectins, with the possible exception of 
Clq (see later) which is included primarily as a 
well-defined example of the structural organisation 
of a serum protein containing both collagen-like 
and globular sequences. All these proteins contain 
a short N-terminal, non-collagen-like sequence 
Volume 250, number 1 FEBSLETTERS June 1989 
Chain 1.2 and 3: 
laa IlGYY IOGXY 
t 
148 aa 
40 aa 
Fig.2. The polypeptide chains of Clq and of soluble lectins 
which contain collagen-like sequences: G-X-Y and the open box 
indicate the presence of Gly-Xaa-Yaa triplet repeats. (f) 
Points of disruption seen in the Gly-Xaa-Yaa repeating 
structure. 
followed by a collagenous region and a C-terminal 
end containing a recognition domain. 
Conglutinin, found in cows [2] and humans [ 191, 
as outlined above, is the first described vertebrate 
lectin. It shows a calcium-dependent binding to N- 
acetyl-D-glucosamine and mannose-terminated 
carbohydrate structures [20]. All available evi- 
dence indicates that conglutinin binds via poly- 
meric mannose structures to a degradation product 
of the major complement component C3 (this de- 
gradation product is an inactivated form of C3b 
which is designated iC3b) [21]. Whether this bind- 
ing is involved in a physiological function of the 
protein is not confirmed, but it has been shown 
that conglutinin exhibits a leucocyte and comple- 
ment-dependent bactericidal activity [22]. In this 
context, it is interesting that consumption of con- 
glutinin during complement activation (bacterial 
infections) in cattle has been demonstrated [23]. 
Partial sequence studies on the bovine molecule in- 
dicates that the conglutinin polypeptide chains are 
composed of a 25 residue non-collagen-like N- 
terminal sequence followed by a 20 kDa collagen- 
like region and a 20 kDa globular C-terminal se- 
quence [16] (fig.2). 
SP-A, present at the surface of the lung alveoli 
as a component of pulmonary surfactant (which is 
involved in the reduction of surface tension), has 
been identified in several species displaying chains 
of 38-40 kDa and containing a lectin-domain 
similar to that found in other soluble lectins. A 
calcium-dependent binding to phospholipids [24] 
and carbohydrates [25] has been demonstrated for 
one SP-A which is composed of disulfide linked 
polypeptides, with the disulfide bonds being posi- 
tioned in the NHz-terminal region preceding a col- 
lagenous domain followed by a COOH-terminal 
non-cohagen domain where ligand binding prob- 
ably occurs. 
Clq could tentatively be grouped with the lectins 
based on the reports of Clq precipitation with 
polysaccharides [26] and based on the ability cer- 
tain lipopolysaccharides have to bind to Clq 
hereby mediating classical pathway activation [27]. 
It has been suggested that the binding of Clq to 
IgGz-molecules may also involve a lectin binding, 
since it has been shown (using a monoclonal an- 
tibody) that classical pathway activation mediated 
by an antibody-antigen complex can be abolished 
if the antibody is non-glycosylated (achieved via 
treatment of the hybridoma cells with tunicamy- 
tin) [28]. However, the reports indicating that Clq 
may contain lectin-like binding ability have to be 
interpreted with caution in view of the recent 
publication (referred to in table 1) which shows 
that a short peptide sequence derived from the Fc 
region of IgG, and which is free of carbohydrate, 
serves as an inhibitor of Clq binding. 
Clq has a molecular mass of 460 kDa and is 
composed of 18 polypeptide chains (6A, 6B and 
6C) each containing a short non-collagen-like N- 
terminal region (2-5 residues) followed by a 
collagen-like region (of approx. 80 residues) and a 
C-terminal globular region (approx. 136 residues). 
The collagen-like regions form 6 triple-helices 
while the globular regions form 6 globular ‘heads’ 
(each ‘head’ being composed of approx. 136 
residues derived from an A, a B and a C chain) 
[ 171. The collagen-like regions are involved in the 
binding or the proenzymes Clr and Cls (the other 
subcomponents of the Cl complex which is the 
first component of the classical pathway of the 
serum complement system) while the C-terminal 
globular heads are involved in ligand binding i.e. 
to the Fc regions of IgG and IgM present in im- 
mune complexes. After binding of immune com- 
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plexes and activation of the proenzymes Clr and 
Cls, within the Cl complex, the activated Clr and 
Cls are rapidly removed by Cl-inhibitor leaving 
the collagenous regions of Clq free to bind to cell 
surface Clq receptors [29]. 
4. STRUCTURAL SIMILARITIES BETWEEN 
THE COLLAGEN-LIKE SOLUBLE 
LECTINS AND Clq 
Chemical and electron microscopy studies of 
SP-A [30] mannan binding protein [15] (Thiel, S. 
and Timpl, R., unpublished electron microscopy 
data) and conglutinin [ 16,3 l] have shown that they 
have the same distinct divisions of collagen-like 
and globular amino acid sequences in peptide 
chains between 24 and 65 kDa (fig.2) and similar 
overall macromolecular organisation. SP-A is dif- 
ficult to distinguish from Clq when viewed in the 
electron microscope, the MBP also shows marked 
similarity to Clq but appears to be mainly found 
as extended tetramers and trimers rather than as a 
close-packed hexamer, while conglutinin is 
organised in a more flexible ‘spider-like’ structure 
(fig.3). All three of these proteins bind car- 
bohydrate, the primary ligand for SP-A probably 
Tr 
Topvew 
being glycolipids, while mannose binding protein 
and conglutinin bind mannose and N-acetyl-D- 
glucose-amine terminated structures (table 1). Pro- 
tein sequence studies have shown that the non- 
collagen-like sequences, which form the globular 
‘heads’ found in the SP-A, conglutinin (Thiel, S. 
and Willis, A.C., unpublished) and mannose bind- 
ing protein, contain the ‘framework’ residues of C- 
type lectin domain [4]. Thus the carbohydrate bin- 
ding is clearly mediated by the globular ‘heads’ in 
these molecules and this binding may be important 
in triggering a variety of recognition and clearance 
mechanisms via the non-lectin domain i.e. the 
collagen-like domain. Like Clq, the SP-A and 
MBPs shows a characteristic bend halfway along 
their collagen-like triple helical regions due to a 
disruption of the -Gly-Xaa-Yaa- repeating pattern 
of amino acids in one or more of the chains involv- 
ed in the formation of the triple helices (fig.4). It 
is possible that this distinctive feature may be of 
importance in the binding of Clq to cell-surface 
receptors. In view of the marked similarity in 
shape and overall dimensions of Clq, SP-A and 
MBP it is not surprising that preliminary evidence 
has been obtained that all three can bind to the 
Clq-receptor (or similar receptors) found on a 
Teiramer: 
Sldewew I Sideview 
Fig.3. Electron microscopy pictures of (from left to right): Clq, SP-A, MBP (trimeric and tetrameric forms) and bovine conglutinin. 
It should be noted that the conglutinin molecule is considerably larger than Clq, SP-A or MBP and is shown at approx. one-third 
the scale used for the other molecules. Underneath the pictures the proposed structure of each protein with distances indicated (with 
kind permission from Dr Isliker, Dr J. Engel and Dr C.J. &rang). 
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(40) 
(40) 
Fig.4. Amino acid sequences found around the midpoints of the 
collagen-like regions seen in Clq [17], MBP [15] and SP-A 
118,391. The numbers in brackets indicate the numbering of 
residues in each chain, with the N-terminal residue of the 
mature polypeptide chain in each case being designated as 1. 
SP-A chains 1, 2 and 3 represent the different amino acid 
sequences derived from cDNA [18] and genomic clones [39]. 
Interruptions in the repeating Gly-Xaa-Yaa sequence are 
underlined. (---) Space introduced in Clq B and C chain 
sequences and in the MBP sequence to allow alignment with the 
Clq A chain sequence. It is therefore predicted that any triple 
helix formed from these collagen-like sequences would show a 
disruption or ‘bend’ in the region of residues 40-50. 
wide variety of lymphoid and other cell types 
[29,32]. The finding that conglutinin is involved in 
leucocyte mediated bactericidal effects after bind- 
ing, presumably via its globular lectin domains 
[221, to the carbohydrate on iC3b attached to 
bacterial cell surfaces, is suggestive that the 
collagen-like regions of this molecule may also in- 
teract with leucocyte cell surface proteins of a 
similar nature to the Clq-receptor. Thus the bind- 
ing of the collagen-like regions of these molecules 
to a common receptor, or to a family of receptors, 
could be of considerable physiological significance 
since this could be a general recognition and 
clearance mechanism for the ligands of Clq, SP- 
A, MBP and conglutinin, i.e. for clearance of im- 
mune complexes, glycolipids and mannose coated 
proteins/cells, respectively. There appears to be a 
further, functional, similarity between Clq and 
MBP since it has been reported [33] that, after 
binding to its ligand, the MBP can activate the 
classical pathway of complement hus suggesting 
that it may be able to mimic the role that the 
collagen-like region of Clq is thought to play in 
the activation of the proenzyme ClrzClsz 
complex. 
Although there is a strong overall similarity in 
structure, especially over the collagen-like regions, 
between Clq and these lectin molecules there is no 
clear amino acid sequence homology between the 
C-terminal ‘globular” domains of the chains of 
Clq with the C-terminal lectin domains in MBP 
and conglutinin, and indeed the most recent data 
concerned with Clq binding to its ligands suggest 
that this binding takes place to peptide rather than 
carbohydrate structures [34]. 
5. CONCLUSION 
The lectins containing collagen-like sequences 
may play important recognition and protective 
roles at early stages of infection prior to the 
development of efficient humoral or cellular im- 
munity. Recent publications [35,36] on MBP ap- 
pear to support this view e.g. since it has been 
shown that human MBP can bind to gp120 of 
HIV-l and prevent entry of the virus into CD4+ 
cell lines [5]. Also, it has been shown that a mouse 
serum factor (designated Ra-reactive factor due to 
its specific reaction with the carbohydrate on the 
Ra chemotype strains of Salmonella and to R2 
strains of E. co& which appears likely to contain 
mouse MBP, is involved in the activation of the 
classical pathway of complement and resulting 
bactericidal effects [36]. The finding that con- 
glutinin exhibits a leucocyte and complement- 
dependent bactericidal activity [22] is also in- 
dicative of the possible importance of the protec- 
tive roles these lectin molecules may play during 
infection. 
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